Get all your news in one place.
100's of premium titles.
One app.
Start reading
The Independent UK
The Independent UK
Health
Stine Jacobsen

New trial explores if weight-loss ingredient could help fight Alzheimer’s

Novo Nordisk’s ambitious trial into whether its blockbuster obesity drug, semaglutide, could treat Alzheimer’s disease has been described as a "lottery ticket" by a senior executive, highlighting its uncertain yet potentially transformative prospects.

The Danish pharmaceutical giant anticipates receiving data from its crucial Alzheimer’s disease trial by the close of 2025.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.